Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Abstract: To gain insights into the characteristics of clinical resistance to lenalidomide, we evaluated the outcomes of 147 consecutive patients with multiple myeloma (MM) homogeneously treated with immunomodulatory imide drugs (IMiDs) pomalidomide and dexamethasone (Pd) for relapsed and/or refract...

Full description

Bibliographic Details
Main Authors: Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios C. Ziogas, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Ioanna Dialoupi, Stavroula Giannouli, Panagiotis Tsirigotis, Sossana Delimpasi, Despina Mparmparousi, Mairylin Spyropoulou-Vlachou, Aikaterini Xirokosta, Evangelos Terpos, Meletios A. Dimopoulos
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952920317420

Internet

http://www.sciencedirect.com/science/article/pii/S2473952920317420

Similar Items